You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 19, 2024

Claims for Patent: 5,925,760


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 5,925,760
Title: Method for preparing N.sup.2 -arylsulfonyl-L-argininamides
Abstract:A method for preparing N.sup.2 -(3-(a hydrogen atom or a lower alkyl)-8-quinolinesulfonyl)-N.sup.G -nitro-L-arginine which comprises the step of condensing N.sup.G -nitro-L-arginine and 3-(a hydrogen atom or a lower alkyl)-8-quinolinesulfonyl chloride. The method achieves an extremely efficient and high yield preparation of N.sup.2 -arylsulfonyl-L-arginineamides that are useful as active ingredients of medicaments. Also provided is a novel N.sup.2 -(3-(a hydrogen atom or a lower alkyl)-8-quinolinesulfonyl)-N.sup.G -nitro-L-arginine compound which can be used as synthetic intermediate for the manufacture of (2R,4R)-4-methyl-1-[N.sup.2 -(3-methyl-1,2,3,4-tetrahydro-8-quinolinesulfonyl)-L-arginyl]-2-piperidine -carboxylic acid.
Inventor(s): Kikumoto; Ryoji (Tokyo, JP)
Assignee: Mitsubishi Chemical Corporation (Tokyo, JP)
Application Number:08/904,555
Patent Claims: 1. A method for preparing N.sup.2 -(3-(a hydrogen atom or a lower alkyl)-8-quinolinesulfonyl)-N.sup.G -nitro-L-arginine which comprises the step of condensing N.sup.G -nitro-L-arginine and 3-(a hydrogen atom or a lower alkyl)-8-quinolinesulfonyl chloride.

2. N.sup.2 -(3-(a hydrogen atom or a lower alkyl)-8-quinolinesulfonyl)-N.sup.G -nitro-L-arginine.

3. A method for preparing a lower alkyl ester of 1-[N.sup.G -nitro-N.sup.2 -(3-(a hydrogen atom or a lower alkyl)-8-quinolinesulfonyl)-L-arginyl]-4-methyl-2-piperidine-carboxylic acid which comprises the step of condensing N.sup.2 -(3-(a hydrogen atom or a lower alkyl)-8-quinolinesulfonyl)-N.sup.G -nitro-L-arginine and a lower alkyl ester of 4-methylpiperidine-2-carboxylic acid.

4. The method according to claim 3, wherein the condensation is carried out in the presence of phosphorus oxychloride.

5. The method according to claim 3, wherein the ester compound is (2R,4R)-4-methylpiperidine-2-carboxylic acid ethyl ester.

6. The method according to claim 4, wherein the ester compound is (2R,4R)-4-methylpiperidine-2-carboxylic acid ethyl ester.

7. A method for preparing a lower alkyl ester of 1-[N.sup.G -nitro-N.sup.2 -(3-(a hydrogen atom or a lower alkyl)-8-quinolinesulfonyl)-L-arginyl]-4-methyl-2-piperidine-carboxylic acid which comprises the steps of:

(a) preparing N.sup.2 -(3-(a hydrogen atom or a lower alkyl)-8-quinolinesulfonyl-N.sup.G -nitro-L-arginine by reacting N.sup.G -nitro-L-arginine with 3-(a hydrogen atom or a lower alkyl)-8-quinolinesulfonyl chloride; and

(b) condensing the N.sup.2 -(3-(a hydrogen atom or a lower alkyl)-8-quinolinesulfonyl)-N.sup.G -nitro-L-arginine obtained in the above step (a) with a lower alkyl ester of 4-methylpiperidine-2-carboxylic acid.

8. A method for preparing (2R,4R)-4-methyl-1-[N.sup.2 -(3-methyl-1,2,3,4-tetrahydro-8-quinolinesulfonyl)-L-arginyl]-2-piperidine -carboxylic acid which comprises the step of hydrolyzing the lower alkyl ester of 1-[N.sup.G -nitro-N.sup.2 -(3-(a hydrogen atom or a lower alkyl)-8-quinolinesulfonyl)-L-arginyl]-4-methyl-2-piperidine-carboxylic acid obtained according to the method of claim 7, and then subjecting the resulting hydrolysate to catalytic hydrogenation.

9. The method according to claim 7, wherein 3-methyl-8-quinolinesulfonyl chloride is used as the 3-(a hydrogen atom or a lower alkyl)-8-quinolinesulfonyl chloride and ethyl (2R,4R)-4-methylpiperidine-2-carboxylate is used as the lower alkyl ester of 4-methylpiperidine-2-carboxylic acid.

10. The method according to claim 8, wherein 3-methyl-8-quinolinesulfonyl chloride is used as the 3-(a hydrogen atom or a lower alkyl)-8-quinolinesulfonyl chloride and ethyl (2R,4R)-4-methylpiperidine-2-carboxylate is used as the lower alkyl ester of 4-methylpiperidine-2-carboxylic acid.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.